CTC BIO (060590) Financial Statements

OverviewFinancialsChecksFilings

In fiscal year 2025, CTC BIO (060590) reported revenue of 123.8 billion KRW.

Income Statement

YearRevenueOp ProfitNet IncomeSource
2025123.8 billion KRW6.2 billion KRW3.2 billion KRW[source]
2024144.4 billion KRW-4.0 billion KRW-5.2 billion KRW[source]
2023137.9 billion KRW-4.6 billion KRW-15.6 billion KRW[source]
2022165.2 billion KRW11.7 billion KRW6.0 billion KRW[source]
2021140.3 billion KRW-2.9 billion KRW-8.0 billion KRW[source]

Balance Sheet

YearTotal AssetsTotal LiabilitiesTotal EquitySource
2025128.8 billion KRW59.7 billion KRW69.1 billion KRW[source]
2024131.8 billion KRW69.5 billion KRW62.3 billion KRW[source]
2023141.7 billion KRW74.9 billion KRW66.8 billion KRW[source]
2022166.9 billion KRW72.1 billion KRW94.8 billion KRW[source]
2021158.3 billion KRW58.5 billion KRW99.8 billion KRW[source]
Financials & Filings: DART (traceable by receipt number) · Prices: Financial Services Commission · Data Sources · Last checked: 2026-08-29 · About · Delisting market cap threshold: KOSPI 5B KRW / KOSDAQ 4B KRW (per listing rules) · This page provides factual information, not investment advice